Nanozymes and the restoration of immune tolerance in autoimmune diseases

Autoimmune diseases (ADs) are characterized by persistent immune dysregulation and oxidative imbalance, yet current therapies largely rely on broad immunosuppression that rarely restores durable immune homeostasis. Growing evidence indicates that reactive oxygen species (ROS) function as both inflammatory mediators and essential immune regulators, limiting the effectiveness of indiscriminate ROS scavenging. Here, we highlight nanozymes as emerging catalytic therapeutics for (ADs) and redefine their role as regulators of redox-guided immune homeostasis. We propose a catalytic redox set-point framework in which nanozymes restore a physiological redox window that supports immune regulation while constraining pathological inflammation. This perspective establishes a unifying mechanistic link between nanozyme catalysis and immune restoration, and outlines future opportunities for tolerance-oriented design and clinical translation.